University of Bonn

Patient engagement (PE) is crucial for improving patient safety, but implementation is challenging. Key barriers include time constraints and low effectiveness of PE activities. Facilitators like supportive organizational culture, education, and clear responsibilities for PE are vital. This study in Germany highlights the need for systematic PE implementation to enhance patient safety and quality of care.

Article sharing options provided by Springer Nature SharedIt initiative, including a shareable link feature.

Simon 2-Stage futility trial design is feasible for early Parkinson's disease treatments, potentially accelerating discovery of new treatments by reducing time, cost, and sample size. The design uses an interim analysis to stop ineffective treatments early, focusing on a 12-month follow-up and a five-point worsening on the UPDRS motor score as primary outcome. However, it has limitations like longer recruitment periods and a higher probability of falsely stopping trials.

A study from the University of Bonn and LMU Munich challenges the modularity of gene enhancers, revealing shared DNA regions influencing multiple body parts in fruit flies. This complexity suggests enhancers' mutations can have broader evolutionary effects, impacting trait development.

Prof. Tanja Schneider, Head of the Institute of Pharmaceutical Microbiology at the University Hospital Bonn and Deputy Coordinator of the DZIF's “New Antibiotics” research area, received the PHOENIX Pharmacy Science Award in the “Pharmaceutical Biology” category for her research on the novel antibiotic Clovibactin, which shows promise against multi-resistant bacteria.

Researchers from the University of Bonn and University Hospital Bonn developed a label-free optical biosensor to study Toll-like receptor (TLR) signaling dynamics, identifying distinct responses to different bacterial lipopolysaccharides, which could aid in drug discovery for diseases like cancer, diabetes, and dementia.

New guidelines for AI use in brain cancer diagnosis and treatment ensure reliable clinical trial results and patient protection, addressing variability in radiologist interpretations and promoting objective AI analysis of tumor images.

TME Pharma reports H1 2024 financial results, significant survival benefit of NOX-A12 + bevacizumab + radiotherapy for glioblastoma, active discussions to out-license NOX-A12, ongoing activities to externalize NOX-E36 development, and extended financial visibility into January 2025.

The European Medicines Agency's CHMP confirmed its initial refusal to authorize pegcetacoplan (Syfovre) for treating geographic atrophy due to AMD, despite support from the European retina community and dissenting CHMP members. The decision was based on concerns over clinical benefits and safety risks associated with eye injections, despite recognizing the unmet need for GA treatment in the EU.

The EMA's CHMP confirmed its initial opinion to refuse marketing authorisation for pegcetacoplan (Syfovre) for treating geographic atrophy due to AMD, despite broad support from the European retina community. Apellis remains committed to expanding access to the treatment in the US and globally.